Based on recommendations received from 21 broker firms in a Bloomberg survey, the consensus rating for Thermo Fisher Scientific was “buy” from 90.5% (or 19) of the firms, “hold” from 9.5% (or two) of the firms, and no “sell” recommendations.
Mostly positive ratings
The above table lists the 15 brokerage firms that provided a target price for Thermo Fisher Scientific (TMO) over the next 12 months. The consensus 12-month target price for Thermo Fisher Scientific was $155.10, amounting to a 9.4% return compared to Thermo Fisher’s last price of $141.80 on January 1, 2016.
The majority of the surveyed firms gave positive ratings to Thermo Fisher, as the company has a strong and diversified product portfolio. It also developed some breakthrough products that dominate the medical technology market. The company is one of the major players in laboratory equipment and services, as well as analytical instruments.
Thermo Fisher has witnessed growth in revenues with an expanding product portfolio and market reach in recent years. The company has also entered new segments and complementary market spaces through various strategic acquisitions. The scale of operations in the emerging markets and strong presence in the United States is expected to drive the company’s future growth and profitability.
Peer firm recommendations
Based on recommendations received from 18 broker firms in a Bloomberg survey, the consensus rating for Becton Dickinson (BDX) was “buy” from 55% of the firms and “hold” from 45% of the firms.
Of the brokerage firms surveyed by Bloomberg, Abbott Laboratories (ABT) was rated “buy” by 68% of the firms and “hold” by 32% of the firms.
Based on recommendations received from 16 brokerage firms in a Bloomberg survey, the consensus rating for Agilent Technologies (A) was “buy” from 52.9% of the firms and “hold from 47.1% of the firms.
Thermo Fisher Scientific accounts for 2.1% of the Health Care Select Sector SPDR ETF’s (XLV) total holdings.